Empagliflozin modulates seizure activity and oxidative stress in rats with epilepsy

Abstract

Drug-resistant epilepsy, a commonly devastating condition, affects more than 50 million people globally. Type 2 diabetes mellitus (T2DM) is associated with an increased risk of neurological disorders, and a potential association between epilepsy and subsequent T2DM has emerged. Inhibiting sodium-glucose linked transporters (SGLTs), which are differentially expressed in the brain, has been shown to reduce epileptic episode activity. This study aimed to evaluate the anticonvulsive effect of empagliflozin in rats with seizures induced by maximal electric shock (MES) and pentylenetetrazol (PTZ). Generalized tonic‒clonic seizures were induced in the rats using an electroconvulsive meter, and pentylenetetrazol was injected to induce absence seizures. The duration of all the stages of seizure and Racine stage scoring (RSS) were performed. Malondialdehyde (MDA), nitric oxide (NO) and reduced glutathione (GSH) levels in the brain tissues were determined. Histopathological analysis of the brain tissues was carried out. A significant (p <0.01) decrease in the duration of tonic hind limb extension (THLE), a significant decrease in the levels of pro-oxidants such as MDA and NO, and an increase in the levels of antioxidants such as GSH were observed in the low dose 10 mg/kg and high dose 20 mg/kg empagliflozin groups compared to the disease control group. Histopathological analysis revealed a greater number of healthy neurons with few dark-stained cells in the treatment groups, suggesting the neuroprotective effect of empagliflozin. The present study showed that empagliflozin modulates epileptic activity. Empagliflozin has a potential role in the management of epilepsy in diabetic patients.

Keywords

• Antioxidants
• Maximal electroshock
• Pentylenetetrazol
• SGLT2 inhibitor
• Epilepsy

Supporting Institution

Nil

Ethical Statement

The study was carried out in accordance with the rules set forth by the Committee for Control and Supervision of Experimentation on Animals (CCSEA), and the protocol was authorized (IAEC/KMC/65/2021) by the Institutional Animal Ethics Committee.

References

1. Abd El-Fattah EE, Saber S, Mourad AAE, et al. (2022). The dynamic interplay between AMPK/NFκB signaling and NLRP3 is a new therapeutic target in inflammation: Emerging role of dapagliflozin in overcoming lipopolysaccharide-mediated lung injury. Biomed Pharmacother. 147:112628. doi: 10.1016/j.biopha.2022.112628.
2. Alachkar A, Łażewska D, Latacz G, et al. (2018). Studies on Anticonvulsant effects of Novel Histamine H3R Antagonists in Electrically and Chemically Induced Seizures in Rats. Int J Mol Sci.19(11):3386. doi:10.3390/ijms19113386
3. Beutler E, Duron O, Kelly BM. (1963). Improved method for the determination of blood glutathione. J Lab Clin Med. 61:882-888. PMID: 13967893.
4. Blunck JR, Newman JW, Fields RK, Croom JE. (2018) Therapeutic augmentation of ketogenic diet with a sodium-glucose cotransporter 2 inhibitor in a super refractory status epilepticus patient. Epilepsy Behav Case Rep. 10:61-64. doi: 10.1016/j.ebcr.2018.05.002.
5. D'Andrea Meira I, Romão TT, Pires do Prado HJ, Krüger LT, Pires MEP, da Conceição PO. (2019). Ketogenic Diet and Epilepsy: What We Know So Far. Front Neurosci. 13:5. doi:10.3389/fnins.2019.00005.
6. Doğan M & Yildizhan K. (2021). Investigation of the effect of paracetamol against on glutamate-induced cytotoxicity in C6 glia cells. Cumhuriyet Science Journal. 42(4), 789-794
7. Erdogan MA, Yusuf D, Christy J, et al. (2018). Highly selective SGLT2 inhibitor dapagliflozin reduces seizure activity in pentylenetetrazol-induced murine model of epilepsy. BMC Neurol. 18(1):81. doi:10.1186/s12883-018-1086-4.
8. Frantseva MV, Perez Velazquez JL, Tsoraklidis G, et al. (2000) Oxidative stress is involved in seizure-induced neurodegeneration in the kindling model of epilepsy. Neuroscience. 97(3):431-435. doi:10.1016/s0306-4522(00)00041-5.

9. Garcia YJ, Rodríguez-Malaver AJ, Peñaloza N. (2005). Lipid peroxidation measurement by thiobarbituric acid assay in rat cerebellar slices. J Neurosci Methods.144(1):127-135. doi: 10.1016/j.jneumeth.2004.10.018.
10. Guisado R, Arieff AI. (1975). Neurologic manifestations of diabetic comas: correlation with biochemical alterations in the brain. Metabolism. 24(5):665-679. doi:10.1016/0026-0495(75)90146-8.
11. Hassanein, Emad H M et al. (2023). Neuroprotective effect of canagliflozin against cisplatin-induced cerebral cortex injury is mediated by regulation of HO-1/PPAR-γ, SIRT1/FOXO-3, JNK/AP-1, TLR4/iNOS, and Ang II/Ang 1-7 signals. Immunopharmacol Immunotoxicol . 45(3): 304-316. doi:10.1080/08923973.2022.2143371.
12. Huang CW, Huang CC, Cheng JT, Tsai JJ, Wu SN. (2007). Glucose and hippocampal neuronal excitability: role of ATP-sensitive potassium channels. J Neurosci Res. 85(7):1468-1477. doi:10.1002/jnr.21284.
13. Lee DU, Kang YJ, Park MK, et al. (2003). Effects of 13-alkyl-substituted berberine alkaloids on the expression of COX-II, TNF-alpha, iNOS, and IL-12 production in LPS-stimulated macrophages. Life Sci. 73(11):1401-1412. doi:10.1016/s0024-3205(03)00435-1.
14. Levine MJ. (2017). Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials. Curr Diabetes Rev. 13(4):405-423. doi:10.2174/1573399812666160613113556.
15. Lu CL, Chang YH, Sun Y, Li CY. (2018). A population-based study of epilepsy incidence in association with type 2 diabetes and severe hypoglycaemia. Diabetes Res Clin Pract. 140:97-106. doi: 10.1016/j.diabres.2018.03.020.
16. Lüttjohann A, Fabene PF, van Luijtelaar G. (2009). A revised Racine's scale for PTZ-induced seizures in rats. Physiol Behav. 98(5):579-586. doi: 10.1016/j.physbeh.2009.09.005.
17. Melo IS, Santos YMO, Costa MA, et al. (2016). Inhibition of sodium glucose cotransporters following status epilepticus induced by intrahippocampal pilocarpine affects neurodegeneration process in hippocampus. Epilepsy Behav. 61:258-268. doi: 10.1016/j.yebeh.2016.05.026.
18. Nadeem M, Memon S, Qureshi K, et al. (2023) Seizing the Connection: Exploring the Interplay Between Epilepsy and Glycemic Control in Diabetes Management. Cureus 15(9): e45606. doi:10.7759/cureus.45606
19. Neal EG, Chaffe H, Schwartz RH, et al. (2008). The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial. Lancet Neurol. 7(6):500-506. doi:10.1016/S1474-4422(08)70092-9.
20. Poppe R, Karbach U, Gambaryan S, et al. (1997). Expression of the Na+-D-glucose cotransporter SGLT1 in neurons. J Neurochem.69(1):84-94. doi:10.1046/j.1471-4159.1997.69010084. x.
21. Rovet JF, Ehrlich RM. (1999). The effect of hypoglycemic seizures on cognitive function in children with diabetes: a 7-year prospective study. J Pediatr. 134(4):503-506. doi:10.1016/s0022-3476(99)70211-8.
22. Sander JW, Novy J, Keezer MR. (2016). The intriguing relationship between epilepsy and type 1 diabetes mellitus. Diabetologia. 59(7):1569-1570. doi:10.1007/s00125-016-3982-8
23. Sarangi SC, Joshi D, Kumar R, Kaleekal T, Gupta YK. (2017). Pharmacokinetic and pharmacodynamic interaction of hydroalcoholic extract of Ocimum sanctum with valproate. Epilepsy Behav.75:203-209. doi: 10.1016/j.yebeh.2017.08.018.
24. Senthilkumar M, Amaresan N, Sankaranarayanan. 2021. Plant-Microbe Interactions: Laboratory Techniques, Springer Protocols Handbooks, https://doi.org/10.1007/978-1-0716-1080-0_25, © Springer Science+Business Media, LLC, part of Springer Nature
25. Smiałowska M, Wierońska JM, Szewczyk B. (2003). Neuroprotective effect of NPY on kainate neurotoxicity in the hippocampus. Pol J Pharmacol. 55(6):979-986. PMID: 14730092.
26. Sudha K, Rao AV, Rao A.(2001). Oxidative stress and antioxidants in epilepsy. Clin Chim Acta.303(1-2):19-24. doi:10.1016/s0009-8981(00)00337-5.
27. Tharmaraja T, Ho JSY, Sia CH, et al. (2022). Sodium-glucose cotransporter 2 inhibitors and neurological disorders: a scoping review. Ther Adv Chronic Dis. 13:20406223221086996. doi:10.1177/20406223221086996.
28. Thijs RD, Surges R, O'Brien TJ, Sander JW.(2019). Epilepsy in adults. Lancet. 393(10172):689-701. doi: 10.1016/S0140-6736(18)32596-0.. PMID: 30686584.3.
29. Tsai KF, Chen YL, Chiou TT, et al. (2021). Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases. Antioxidants (Basel). 10(8):1166. doi:10.3390/antiox10081166.
30. Wiciński M, Wódkiewicz E, Górski K, Walczak M, Malinowski B. (2020). Perspective of SGLT2 Inhibition in Treatment of Conditions Connected to Neuronal Loss: Focus on Alzheimer's Disease and Ischemia-Related Brain Injury. Pharmaceuticals (Basel). 13(11):379. doi:10.3390/ph13110379.